Data about the influence of the type of sedation on yield, complications, and tolerance of EBUS-TBNA is mostly based on retrospective studies and is largely inconsistent. Our randomized trial shows that the use of general anesthesia does not improve any of the above-mentioned outcomes. These findings are of critical importance since general anesthesia is not accessible to all bronchoscopists, and it implies a larger use of resources. Dr. Casal contributed to the study design, data collection, Institutional Review Board application, EBUS performance, statistical analysis, data interpretation, and manuscript composition and revision. He had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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INTRODUCTION:
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has become one of the most important tools in the armamentarium of pulmonologists and thoracic surgeons. It is a safe and effective technique for sampling of hilar and mediastinal lymph nodes and masses (1) (2) (3) (4) and it is now considered the initial choice for histologic sampling of the mediastinum in lung cancer staging (5) . Two common types of sedation used for EBUS-TBNA include moderate sedation (MS) and general anesthesia (GA). Although accurate information regarding physician's use of sedation in EBUS-TBNA is unknown, lack of uniform access to GA in majority of clinical practice setting has favored the use of MS (3) . A remaining question is the impact of the type of sedation on the diagnostic yield of EBUS-TBNA. Although initial retrospective analysis of these two types of sedation suggested there was no significant difference in the diagnostic yield, a more recent study from Yarmus and coworkers reported a much greater diagnostic yield when EBUS was performed under GA (6) . These findings may generate concern among many physicians who perform EBUS-TBNA in non-tertiary settings where access to GA is limited or not available.
Another important factor in physician's choice for use of GA or MS centers on the rate of complications associated with sedation utilized; however, little is known about the complications related to the type of sedation utilized for EBUS-TBNA. The AQuIRE data registry found an association between GA and greater need for post-procedure escalation of care (7) . Unfortunately, the available data is also based on retrospective studies and it is somewhat inconsistent. Given the widespread use of EBUS-TBNA and 8 the fact that GA is not readily available for bronchoscopy in many institutions, it is important to assess the effect of the type of sedation on EBUS-TBNA outcomes.
We conducted a randomized clinical trial to evaluate the impact of the type of sedation (GA vs. MS) on the diagnostic yield of EBUS-TBNA, on complications, and on patients' tolerance. Some of the results of this study have been previously reported in the form of an abstract (8) .
MATERIALS AND METHODS
Subjects
We enrolled both outpatients and hospitalized patients older than 18 years of age requiring EBUS-TBNA based on suspicion of either benign or malignant disease in mediastinal or hilar LNs or masses, or requiring EBUS-TBNA for mediastinal staging of lung cancer. Exclusion criteria included: suspected need for additional procedures other than EBUS-TBNA during planned bronchoscopy (e.g. need for navigational bronchoscopy, endobronchial biopsies, therapeutic bronchoscopy), history of intolerance to moderate sedation, allergies to any of the involved sedatives or anesthetic agents, comorbidities contraindicating EBUS procedure, pregnancy, or inability to obtain informed consent. The study was performed at the Michael E. DeBakey VA Medical Center, and it was approved by the Institutional Review Board at Baylor College of Medicine. Written informed consent was obtained prior to enrollment of all patients.
Study Design
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The study was a prospective randomized controlled trial of EBUS-TBNA performed under either GA versus MS with a 1:1 computer-generated randomization.
Cytologists were blinded to the type of sedation utilized for EBUS-TBNA. The primary endpoint was diagnostic yield of EBUS-TBNA, defined as the number of subjects in which EBUS-TBNA provided a specific diagnosis. A specific diagnosis was defined as any kind of malignancy, infection (i.e. histoplasmosis, tuberculosis), or sarcoidosis. The presence of lymphocytes was only considered as an adequate sample, but not as a specific diagnosis. Sample adequacy was evaluated as a secondary endpoint. For LNs, an "adequate" sample was defined as either a specific diagnosis or lymphocytes, while an "inadequate" sample was one with blood, bronchial cells or necrosis, and without a diagnosis or lymphocytes. Only samples with a specific diagnosis were considered "adequate" when lung masses were biopsied. Sensitivity of EBUS-TBNA to detect a specific diagnosis was another secondary endpoint. A "true negative" result required either confirmation by surgery (surgical lymph node dissection or mediastinoscopy) or 6 months of radiographic follow up by CT or integrated PET-CT demonstrating stability or decrease in size without new lesions. Other secondary endpoints included: "procedure time" as measured from the initial bronchoscope introduction until last bronchoscope removal from the airway; "EBUS-TBNA time", measures from the insertion to the final removal of the EBUS bronchoscope; number of LN sampled per patient; number of biopsies per LN; size of LN; EBUS-related complications (i.e. bleeding, pneumothorax, mediastinitis or mediastinal abscess); sedation/anesthesia related complications such as hypotension (defined as a drop of systolic blood pressure to less than 90 mm Hg requiring intervention -fluids or vasopressors-), hypertension (an increase in mean arterial pressure of > 30% from baseline in 3 separate readings), hypoxemia (oxygen saturation < 90% for > 1 min-, or hypoxemia requiring intervention such as nonrebreathing mask, "bagging", or mechanical ventilation), arrhythmia requiring antiarrhythmic medications, excessive coughing which prevented the procedure from being completed, and inadequate sedation despite maximum pre-defined sedative doses.
Major complications were those that resulted in life-threatening conditions, disability, additional interventions required to prevent death or disability, need for escalation of care post procedure (such as admission for outpatients or intensive care unit admission for any patient), extended hospital length of stay, and death. Time to recovery from anesthesia was assessed with Aldrete's Score (defining time 0 when patient is transferred from surgical table to stretcher, and checking score every 15 min until a score of 8 points was reached) (see Appendix A) (9) . Patient tolerance to procedure was also evaluated as a secondary endpoint with an anonymous Likert's scale type questionnaire provided to patients before discharge (see Appendix A).
Study Procedures
Randomization was created by a computer program and results were made available to the study personnel after enrollment of each patient, prior to the procedure in order to have anesthesia team available when indicated. All procedures were carried out in a single bronchoscopy suite. Patients randomized to GA group received total intravenous anesthesia in a standard fashion and had a laryngeal airway mask placed (a combination of the following drugs was allowed: propofol, ramifentanyl, etomidate, ketamine, cisatracurium, rocuronium, succinyl coline). Following the definitions of the depth of sedation from the American Society of Anesthesia, our patients were allowed to 11 fluctuate between deep sedation and general anesthesia as needed (10). Deep sedation was defined as a drug-induced depression of consciousness during which patients cannot be easily aroused but responds to repeated or painful stimulation, with potential impairment of independent ventilation and potential need for an artificial airway. General anesthesia was defined as drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation, they cannot maintain spontaneous ventilation, and they require an artificial airway (10). Those who were randomized to MS group, in addition to topical 1% lidocaine, received a combination of midazolam (up to 0.1 mg/kg) and fentanyl (up to 150 mcg) following local hospital sedation policies aiming at a moderate degree of sedation (RASS score of 2-3). Moderate sedation was defined as a drug-induced depression of consciousness during which patients respond purposefully to verbal commands or light tactile stimuli, with no interventions required to maintain a patent airway or ventilation (10). EBUS-guided transbronchial needle biopsy was performed using a real-time ultrasound biopsy bronchoscope (BF-UC-180F; Olympus Ltd.; Tokyo, Japan). A 7.5-MHz linear ultrasound transducer with a maximum penetration of 50 mm was linked to a processor (EU-ME1;Olympus Ltd.; Tokyo, Japan).
Transbronchial needle biopsies were performed using a dedicated 22-gauge needle (NA-201SX; Olympus). Two needles were utilized for every patient as part of our standard practice (while the assistant is retrieving the sample from the first needle, the operator is already taking a new sample with the second needle). Rapid on-site cytology examination (ROSE) was available in all procedures. When staging for lung cancer, all LN that were ≥ 5 mm in short axis by EBUS (both mediastinal and hilar) were sampled in the standard N3 to N2 to N1 fashion. A minimum of 3 needle-biopsies was performed at each target (a maximum of 6 was allowed, particularly for patients who based on the on-site report 12 required additional testing such as cultures, molecular testing, or flow cytometry) (11).
One slide was prepared from each pass and the rest of the material was placed in Sacomano solution for cell-block preparation. EBUS-TBNA was performed by an interventional pulmonologist (RC), and no trainees were involved. While ROSE was performed by different staff pathologists, all final cytology results were assessed by a single experienced lung cytopathologist (LG). All pathologists were blinded to the group assignment.
Statistical Analysis
The primary analysis of this study was diagnostic yield, defined as percentage of patients in which EBUS-TBNA biopsy rendered a specific diagnosis. Utilizing Bayesian analysis, a sample size of 75 patients per study group has a probability of 91% to detect 10% difference in diagnostic yield, assuming a non-informative beta (1.0, 1.0) prior distribution for diagnostic yield for each study group. Summary statistics were used to describe the study population in each group. Pearson's chi-squared test (or Fisher's exact test) and t-test (or Wilcoxon's rank sum test) were used to determine difference between the study groups. Results were calculated using an intent-to-treat analysis.
Statistical analysis was performed using Stata/SE version 13.1 statistical software (Stata Corp. LP, College Station, TX).
RESULTS
Between November 2011 and July 2013, 234 consecutive patients referred for EBUS-TBNA were assessed. A total of 149 patients were randomized and underwent EBUS-TBNA: 75 patients to GA group and 74 to MS group (Figure 1 5.3%) (p<0.001) ( Table 4) . Patients in the MS group recalled the procedure more often (p<0.001) while patients in the GA group had greater shortness of breath post procedure (p=0.016). However, the majority of the patients would agree to undergo the same procedure again in the future in both groups (p=0.355) ( Table 5) .
DISCUSSION
This is the first randomized study that aimed to determine the contribution of two commonly used modes of sedation on the outcome of EBUS-TBNA. Previous publications that address the impact of the types of sedation on EBUS-TBNA outcomes have been predominantly based on retrospective analyses, and have provided inconsistent information (2, 3, 6) . In this randomized controlled trial we demonstrate for the first time that GA and MS do not significantly affect the diagnostic yield and sensitivity of EBUS-TBNA. Consistently, we demonstrate that there are no significant differences in patients' tolerance or major complications associated with GA or MS in patients undergoing EBUS-TBNA.
Initial retrospective reports suggested no difference in diagnostic yield of EBUS-TBNA performed under either MS or GA (2, 3). However, this data came from sub-group analysis or analysis of sedation type as one of multiple factors that can influence the yield of EBUS-TBNA. Yarmus and coworkers specifically evaluated the influence of the type of sedation on the diagnostic yield of EBUS-TBNA, and reported a greater diagnostic yield when EBUS was performed under deep sedation (patients had an LMA or 15 endotracheal tube, were monitored by anesthesiologists, but were allowed to breathe spontaneously) (6) . This study compared EBUS-TBNA performed in two different centers of excellence in interventional pulmonology, one performing all cases under MS and the other one performing all cases under deep sedation. The authors recognized their main limitation as the fact that procedures were done in two different institutions. This can potentially lead to multiple confounding factors influencing their results (potentially different populations, different individuals performing EBUS, different pathologists, etc.). The authors speculate that deep sedation allowed the pulmonologist for more lymph nodes to be sampled and for more needle passes per site, resulting in improved overall diagnostic yield (80% vs. 66%). Interestingly, the fact that GA allows for biopsy of more LN was also noticed in the AQuIRE data registry (3) . In contrast to these findings, our study has found no significant differences in diagnostic yield between study groups, and also no difference in the number of LN that were sampled, their size, or the number of biopsies per LN. Moreover, the average number of LN per patient sampled in our MS group was as high or even higher than the average number of LN sampled in the deep sedation group of Yarmus's study (6) . Our diagnostic yield rates are comparable to those previously reported (3). While we found a statistically significant difference in sample adequacy between the two groups, we do not consider the 2% difference (98% vs. 100%) clinically relevant.
In our study, both the total duration of bronchoscopy as well as EBUS-TBNA time was shorter in the MS group. The duration of our procedures was well within the ranges that have been previously reported (1, 2, 4, 12) . But our findings are in sharp contrast of those reported by Yarmus and coworkers, which found longer procedural time 16 associated with MS (46.9 vs. 36.4 min) (6) . A potential explanation might be the lack of trainees in our study, speculating that trainees can potentially take longer time to sample LN under MS with patients possibly moving or coughing. We believe that the difference we found (shorter procedures in MS group) might have been secondary to the fact that the bronchoscopy team might have acted more expeditiously when patients were not deeply sedated. For obvious reasons the bronchoscopy team could not be blinded to the group allocation in order to avoid this bias. In addition, we utilized two needles for each procedure, which may have shortened our procedure duration.
Our study is also the first one to compare post-procedure recovery time in patients undergoing EBUS-TBNA under MS and GA. The shorter time to recovery expected with GA (due to the shorter half life of drugs) was not seen in our study, in which all patients in both groups reached an Aldrete's score of 8 within 15 minutes of recovery.
Five patients in the MS group (6.7%) did not tolerate the procedure due to inadequate sedation despite reaching maximum pre-established doses of sedatives. The results of these patients were analyzed in the MS group following the intention to treat analysis.
Most of these patients were previously taking either benzodiazepines as anxyiolitics or sedatives (2 patients), or opioids for pain management (2 patients). EBUS-TBNA was completed under GA in all these five cases, without changing the final results in any of them. Nevertheless, it is important to highlight that a small percentage of cases may not tolerate the procedure under MS and may require GA.
Data on the impact of the type of sedation on EBUS-TBNA complications is scant and retrospective in nature. The AQuIRE Data registry found in multivariate analysis that the use of GA was associated with greater escalation of care, but they reported only 1.4% escalation of care under GA vs. 0.4% escalation of care under MS (7) . None of our patients in either group experienced a major complication or required escalation of care.
We found a greater amount of minor sedation-related complications in the MS group. All complications that occurred in either group were resolved by the end of the procedure and, by definition, resulted in no escalation of care, prolonged length of stay, disability, or death. Some patients experienced more than one complication. While the most common minor complication was hypotension in the GA group (common during the induction phase of anesthesia), in the MS group hypertension, tachyarrhythmia, and transient hypoxemia were found more often. These are likely due to the inability to sedate or keep the patients sedated at the target RASS score (2-3) during the entire length of the procedure. We also believe that the high rate of minor complications may be due to the use of very strict definitions and thorough documentation, which are an essential component of prospective studies.
Steinfort and coworkers prospectively studied patient's satisfaction after EBUS-TBNA under MS (13) . In their study, satisfaction was extremely high, with 40 patients (98%) reporting they would "definitely return" for EBUS-TBNA in the future if required.
It is importance to highlight that 68% (28/41) of their patients received propofol as part of their moderate sedation. Unlike in other parts of the world, in the United States propofol is typically considered an anesthetic drug and it can only be administered by anesthesiologists. In our study, we found no significant difference in patient satisfaction between both groups. Not surprisingly, more patients recalled the procedure in the MS group.
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The main limitation of our study is that it was performed in a single center with a highly experienced operator, limiting the generalizability of its results to experienced operators. The latter are becoming more common with the rapid adoption of EBUS training in pulmonary and thoracic surgery fellowships, and with the increase in the number of interventional pulmonology fellowships in the past few years. We did not allow trainees to participate in our study because their level of training and EBUS proficiency is very heterogeneous. In our experience, teaching EBUS prolongs procedures and that could directly affect our outcomes. Hence, our results do not apply to procedures in which novice trainees are being taught how to perform EBUS-TBNA.
Another limitation mentioned above is the unavoidable lack of blinding of the operator.
Our population differs from the general population with the vast majority of subjects being male and with greater comorbidities as evidenced by a high ASA score. Though these factors might affect complication rates and patient's tolerance, they are highly unlikely to impact diagnostic yield of EBUS-TBNA.
In daily practice the choice of type of sedation should be tailored to factors associated with the operator, the patient, and the procedure itself. Less experienced operators or teaching facilities may benefit from the use of GA. Patient's history of intolerance to moderate sedation or significant home-use of benzodiazepines or opioids may also indicate the need for GA. GA may also be preferable in prolonged cases when additional procedures are required (i.e. sampling of peripheral tumor, fiducial marker placement).
In conclusion, in this prospective randomized trial, we show that the type of sedation utilized does not impact the diagnostic yield, rate of major complications, or 19 patient tolerance of EBUS-TBNA. We believe our results are highly relevant since many centers do not have access to GA in bronchoscopy suites, sometimes requiring the use of operating rooms, which could potentially lead to higher costs. Future prospective multicenter studies are required to corroborate our findings.
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